"Cardiovascular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.
| Descriptor ID |
D002317
|
| MeSH Number(s) |
D27.505.954.411
|
| Concept/Terms |
Cardiovascular Agents- Cardiovascular Agents
- Agents, Cardiovascular
- Cardiovascular Drugs
- Drugs, Cardiovascular
|
Below are MeSH descriptors whose meaning is more general than "Cardiovascular Agents".
Below are MeSH descriptors whose meaning is more specific than "Cardiovascular Agents".
This graph shows the total number of publications written about "Cardiovascular Agents" by people in this website by year, and whether "Cardiovascular Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2009 | 3 | 1 | 4 |
| 2010 | 2 | 1 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 2 | 0 | 2 |
| 2014 | 3 | 2 | 5 |
| 2015 | 3 | 1 | 4 |
| 2016 | 6 | 1 | 7 |
| 2017 | 75 | 22 | 97 |
| 2018 | 59 | 26 | 85 |
| 2019 | 18 | 10 | 28 |
| 2020 | 5 | 5 | 10 |
| 2021 | 4 | 5 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Cardiovascular Agents" by people in Profiles.
-
Adverse effects, pharmacological interactions, and cardiovascular drugs in COVID-19 treatment. Arch Cardiol Mex. 2021 Dec 20; 91(Suplemento COVID):079-085.
-
Changes in Purchases for Intensive Care Medicines During the COVID-19 Pandemic: A Global Time Series Study. Chest. 2021 12; 160(6):2123-2134.
-
Increased pharmacy purchases of cardiovascular drugs from wholesalers prior to the first and second COVID-19 lockdowns. Int J Clin Pharmacol Ther. 2021 Aug; 59(8):572-577.
-
Cardiovascular drug therapy and surrogate COVID-19 outcomes: which is the impact of the "miraculous" sodium-glucose co-transporter-2 inhibitors? Kardiol Pol. 2021; 79(9):1048-1049.
-
Cardiovascular drug therapy and surrogate COVID-19 outcomes: which is the impact of the "miraculous" sodium-glucose co-transporter-2 inhibitors? Author's reply. Kardiol Pol. 2021; 79(9):1050-1051.
-
Cardiovascular drugs and COVID-19 clinical outcomes: A living systematic review and meta-analysis. Br J Clin Pharmacol. 2021 12; 87(12):4534-4545.
-
Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. Pharmacol Rev. 2021 07; 73(3):924-967.
-
COVID-19 and cardiovascular system-a comprehensive review. Rev Cardiovasc Med. 2021 06 30; 22(2):343-351.
-
Severe Exacerbations of Systemic Capillary Leak Syndrome After COVID-19 Vaccination: A Case Series. Ann Intern Med. 2021 10; 174(10):1476-1478.
-
Association between cardiovascular disease, cardiovascular drug therapy, and in-hospital outcomes in patients with COVID-19: data from a large single-center registry in Poland. Kardiol Pol. 2021; 79(7-8):773-780.